Staphylococcus aureus Pneumonia: Emergence of MRSA in the Community

ABSTRACT

The clinical presentation of staphylococcal pneumonia is changing. Healthy young people without traditional risk factors for Staphylococcus aureus disease are presenting with severe necrotizing infection and high mortality. The clinical picture is reminiscent of outbreaks of postinfluenzal staphylococcal pneumonia seen in the past century. Most of these staphylococcal strains are methicillin-resistant and are not health care associated. Many strains contain toxins that are likely responsible for the severity of illness seen. Panton-Valentine leukocidin has rarely been identified in S. aureus until recently. It appears that the genetic element for methicillin resistance has been introduced into multiple highly virulent methicillin-susceptible strains with great potential for further spread. Early recognition and treatment of possible community-acquired methicillin-resistant S. aureus (CA-MRSA) is essential. It is equally important to attain microbiological confirmation of the diagnosis for optimal treatment and to initiate appropriate infection control procedures.

KEYWORDS

Methicillin resistance - pneumonia - staphylococci

REFERENCES

• 1 Garner J S, Jarvis W R, Emori T G et al.. CDC definitions for nosocomial infections.  Am J Infect Control. 1988;  16 128-140
• 2 Cookson B D. Methicillin-resistant Staphylococcus aureus in the community: new battlefronts, or are the battles lost?.  Infect Control Hosp Epidemiol. 2000;  21 398-403
• 3 Zetola N, Francis J S, Nuermberger E L, Bishai W R. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat.  Lancet Infect Dis. 2005;  5 275-286
• 4 Salgado C D, Farr B M, Calfee D P. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors.  Clin Infect Dis. 2003;  36 131-139
• 5 Saravolatz L D, Pohlod D J, Arking L M. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks.  Ann Intern Med. 1982;  97 325-329
• 6 Centers for Disease Control and Prevention . Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997-1999.  Morb Mortal Wkly Rep. 1999;  48 707-710
• 7 Herold B C, Immergluck L C, Maranan M C et al.. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk.  JAMA. 1998;  279 593-598
• 8 Said-Salim B, Mathema B, Kreiswirth B N. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen.  Infect Control Hosp Epidemiol. 2003;  4 451-455
• 9 Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey.  Clin Infect Dis. 2005;  40 562-573
• 10 Mongkolrattanothai K, Boyle S, Kahanna M D et al.. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates.  Clin Infect Dis. 2003;  37 1050-1058
• 11 Chambers H F. Community-associated MRSA-resistance and virulence converge.  N Engl J Med. 2005;  352 1485-1487
• 12 Urth T, Juul G, Skov R et al.. Spread of methicillin-resistant Staphylococcus aureus ST80-IV clone in a Danish community.  Infect Control Hosp Epidemiol. 2005;  26 144-149
• 13 Hausmann W, Karlish A J. Staphylococcal pneumonia in adults.  BMJ. 1956;  2 845-847
• 14 Kaye M G, Fox M J, Bartlett J G et al.. The clinical spectrum of Staphylococcus aureus pulmonary infection.  Chest. 1990;  97 788-792
• 15 Laupland K B, Church D L, Mucenski M et al.. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections.  J Infect Dis. 2003;  187 1452-1459
• 16 Musher D M, Lamm N, Darouiche R O et al.. The current spectrum of Staphylococcus aureus infection in a tertiary care hospital.  Medicine. 1994;  73 186-208
• 17 Fridkin S K, Hageman J C, Morrison M et al.. Methicillin-resistant Staphylococcus aureus in three communities.  N Engl J Med. 2005;  352 1436-1444
• 18 Naimi T S, LeDell K H, Como-Sabetti K et al.. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection.  JAMA. 2003;  290 2976-2984
• 19 Chickering H T, Park J H. Staphylococcus aureus pneumonia.  JAMA. 1919;  72 617-626
• 20 Ede S, Davis G M, Holmes F H. Staphylococcic pneumonia.  JAMA. 1959;  170 638-643
• 21 Reimann H A. Primary staphylococcic pneumonia.  JAMA. 1933;  101 514-520
• 22 Gallis H A. Subacute staphylococcal pneumonia in renal transplant recipient.  Am Rev Respir Dis. 1975;  112 109-112
• 23 Watanakunakorn C. Bacteremic Staphylococcus aureus pneumonia.  Scand J Infect Dis. 1987;  19 623-627
• 24 Wiita R M, Cartwright R R, Davis J G. Staphylococcal pneumonia in adults: a review of 102 cases.  Am J Roentgenol. 1961;  86 1083-1091
• 25 Bentley D W. Staphylococcal pneumonia: coping with a medical emergency.  J Respir. 1980;  1 23-41
• 26 Naraqi S, McDonnell G. Hematogenous staphylococcal pneumonia secondary to soft tissue infection.  Chest. 1981;  79 173-175
• 27 Musher D M, Franco M. Staphylococcal pneumonia: a new perspective.  Chest. 1981;  79 172-173
• 28 Fisher A M, Trever R W, Curtin J A et al.. Staphylococcal pneumonia: a review of 21 cases in adults.  N Engl J Med. 1958;  256 919-928
• 29 Johnston B L. Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia: a critical review.  Semin Respir Infect. 1994;  9 199-206
• 30 Cafferkey M T, Abrahamson E, Bloom A et al.. Pulmonary infection due to methicillin-resistant Staphylococcus aureus .  Scand J Infect Dis. 1988;  20 297-301
• 31 Gonzalez C, Rubio M, Romero-Vivas J et al.. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms.  Clin Infect Dis. 1999;  29 1171-1177
• 32 Rello J, Torres A, Ricart M et al.. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes.  Am J Respir Crit Care Med. 1994;  150 1545-1549
• 33 Healy C M, Hulten K G, Palazzi D L et al.. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit.  Clin Infect Dis. 2004;  39 1460-1466
• 34 Francis J S, Doherty M C, Lopatin U et al.. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes.  Clin Infect Dis. 2005;  40 100-107
• 35 Dufour P, Gillet Y, Bes M et al.. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: Emergence of a single clone that produces Panton-Valentine leukocidin.  Clin Infect Dis. 2002;  35 819-824
• 36 Kravitz G R, Dries D J, Peterson M L et al.. Purpura fulminans due to Staphylococcus aureus .  Clin Infect Dis. 2005;  40 941-947
• 37 Gillet Y, Issartel B, Vanhems P et al.. Association between lethal Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients.  Lancet. 2002;  359 753-759
• 38 Boussaud V, Parrot A, Mayaud C et al.. Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus .  Intensive Care Med. 2003;  29 1840-1843
• 39 Le Thomas I, Mariani-Kurkdjian P, Collignon A et al.. Breast milk transmission of a Panton-Valentine leukocidin-producing Staphylococcus aureus strain causing infantile pneumonia.  J Clin Microbiol. 2001;  39 728-729
• 40 Hsu L-Y, Koh T-H, Kurup A et al.. High incidence of Panton-Valentine leukocidin-producing Staphylococcus aureus in a tertiary care public hospital in Singapore.  Clin Infect Dis. 2005;  40 486-489
• 41 Panton P N, Valentine F CO. Staphylococcal toxin.  Lancet. 1932;  1 506-508
• 42 Lina G, Piemont Y, Godall-Gamot F et al.. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.  Clin Infect Dis. 1999;  29 1128-1132
• 43 Chambers H F. Staphylococcal purpura fulminans: a toxin-mediated disease?.  Clin Infect Dis. 2005;  40 948-950
• 44 Miller L G, Perdreau-Remington F, Rieg G et al.. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles.  N Engl J Med. 2005;  352 1445-1453
• 45 Fowler V G, Li J, Corey R G et al.. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients.  J Am Coll Cardiol. 1997;  30 1072-1078
• 46 Moise P A, Schentag J J. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infection.  Int J Antimicrob Agents. 2000;  16 S31-S34
• 47 Georges H, Leroy O, Alfandari S et al.. Pulmonary disposition of vancomycin in critically ill patients.  Eur J Clin Microbiol Infect Dis. 1997;  16 385-388
• 48 Moellering R C. Linezolid: the first oxazolidinone antimicrobial.  Ann Intern Med. 2003;  138 135-142
• 49 Stevens D L, Herr D, Lampiris H et al.. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.  Clin Infect Dis. 2002;  34 1481-1490
• 50 Kollef M H, Rello J, Cammarata S K et al.. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin.  Intensive Care Med. 2004;  30 388-394
• 51 Rubinstein E, Cammarata S K, Oliphant T H et al.. Linezolid (PNU-10076) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.  Clin Infect Dis. 2001;  32 402-412
• 52 Wunderink R G, Rello J, Cammarata S K et al.. Linezolid versus vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.  Chest. 2003;  124 1789-1797
• 53 Powers J H, Ross D B, Lin D et al.. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia.  Chest. 2004;  126 314-316
• 54 Eliopoulos G M. Quinupristin-dalfopristin and linezolid: evidence and opinion.  Clin Infect Dis. 2003;  36 473-481
• 55 Fagon J- Y, Patrick H, Haas D W et al.. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin.  Am J Respir Crit Care Med. 2000;  161 753-762
• 56 Scotton P G, Rigoli R, Vaglia A. Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens.  Infection. 2002;  30 161-163
• 57 Carpenter C F, Chambers H F. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.  Clin Infect Dis. 2004;  38 994-1000
• 58 Adra M, Lawrence K R. Trimethoprim-sulfamethoxazole for treatment of severe Staphylococcus aureus infections.  Ann Pharmacother. 2004;  38 338-341
• 59 Ruhe J J, Monson T, Bradsher R W, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature.  Clin Infect Dis. 2005;  40 1429-1434
• 60 Lewis J S, Jorgensen J H. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned.  Clin Infect Dis. 2005;  40 280-285
• 61 Gauduchon V, Cozon G, Vandenesch F et al.. Neutralization of Staphylococcus aureus Panton-Valentine leukocidin by intravenous immunoglobulin in vitro.  J Infect Dis. 2004;  189 346-353